Global GI & Rare Disease Franchise Leader

Alfasigma; Antwerpen; Remote; EUR 180,000 - 260,000; Full time

Job summary

Alfasigma is seeking a Sr. Director, Global Franchise Head for Gastroenterology & Rare Disease to define and execute the global TA strategy. You will lead brand planning, allocate resources, and partner with R&D, Medical Affairs, and commercial teams to build a differentiated franchise.

The role requires extensive international pharma experience, strong leadership, and a track record of strategic execution across GI and rare diseases. Expect global impact and senior stakeholder visibility.

Qualifications

• Significant international pharmaceutical experience in Marketing, Franchise Leadership, or General Management.
• Proven track record in Gastroenterology, Rare Diseases, Specialty Care, and/or Specialty Pharmaceuticals.
• Demonstrated success in defining and executing Therapeutic Area strategies.
• Strong people leadership and talent development capabilities.

Responsibilities

• Define and co-lead the long-term Gastroenterology & Rare Disease TA strategy with R&D and partners.
• Translate insights into a 'where to play' and 'how to win' franchise plan; align pipeline with priorities.
• Drive cross-functional decision-making and resource allocation to maximize franchise value.
• Lead and develop a high-performing Global Brand Managers team.

Skills

International pharma experience

Gastroenterology & Rare Diseases

Therapeutic Area strategy

Cross-functional leadership

Stakeholder management

Job description

Alfasigma is seeking a Sr. Director, Global Franchise Head for Gastroenterology & Rare Disease to define and execute the global TA strategy. You will lead brand planning, allocate resources, and partner with R&D, Medical Affairs, and commercial teams to build a differentiated franchise.

The role requires extensive international pharma experience, strong leadership, and a track record of strategic execution across GI and rare diseases. Expect global impact and senior stakeholder visibility.